We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral Relugolix Equals Standard ADT, Slashes Cardiac Events in Patients with Advanced Prostate Cancer.
- Authors
Starr, Phoebe
- Abstract
The article discusses the phase 3 HERO study in 2020. Results showed that oral relugolix given daily is superior to standard androgen-deprivation therapy (ADT) with leuprolide (Lupron) in men with advanced prostrate cancer, and that the treatment showed sustained testosterone suppression and led to a 54% lower risk of major cardiovascular events. Also noted is relugolix's comparatively faster effect.
- Subjects
LUTEINIZING hormone releasing hormone antagonists; ANTIANDROGENS; CANCER patients; DRUG side effects; HETEROCYCLIC compounds; ORAL drug administration; PROSTATE tumors
- Publication
American Health & Drug Benefits, 2020, Vol 13, p1
- ISSN
1942-2962
- Publication type
Article